

BSW Formulary Update – Following APC January 2021 meeting *(January meeting cancelled due to operational pressures. Decisions agreed by committee outside the meeting via email)*

New additions to the BSWformulary

- [COVID vaccines](#) – for use in line with vaccination programme. GREEN TLS
- [LAT gel](#) (lidocaine 4%, adrenaline 0.1% and tetracaine 0.5%, 3ml sterile gel) added for use in paediatrics in accident and emergency setting. RED TLS
- [Sumatriptan 3mg/0.5ml](#) solution for injection – new lower strength product added in line with BNF update to dosing for treatment of acute migraine in adults: *Initially 3–6 mg for 1 dose, followed by 3–6 mg after at least 1 hour if required, to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack), administered using an auto-injector.* GREEN TLS
- [Dovato](#) (50mg dolutegravir and 300mg lamivudine tablets) – added in line with NHSE commissioning position for use in HIV. RED TLS
- [Esomeprazole GR granules for oral suspension 10mg](#) – added for use in children 1 – 11 years and ≥ 10 kg who have not tolerated MUPS or who have enteral tubes in situ. GREEN TLS

Traffic Light Status (TLS) Aligned for BSW

- [Isavuconazole](#) - added for GWH for use in line with NHSE commissioning position (previously listed only at RUH). RED TLS
- [Esomeprazole 20mg and 40mg gastro-resistant tablets](#) –aligned with GREEN TLS for BSW. For use in patients with swallowing difficulties, or with NG/PEG tubes in-situ; tablets are licensed for administration via gastric tube following dispersal in non-carbonated water.
- [Ciclosporin](#) (oral) changed from AMBER to RED TLS for GWH dermatology indications

New and Updated Prescribing Guidelines

- **New** - [BSW Prescribing Guidance for Oral Semaglutide](#)

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswccg.formulary@nhs.net

What the BSW CCG formulary team are currently working on

- Producing a policy/pathway and prescribing criteria for use of melatonin
- Updating the Vitamin D guidance
- Updating the constipation guidance and other gastro guidance from BSWformulary Chapter 1
- Working on the Paediatric formulary chapter
- Reviewing formulary position of Cox-2 inhibitors
- Working with AWP on an oral antipsychotic SCA
- Guidance for high dose fexofenadine for urticarial
- SCA for postural hypotension
- Adding neurology indications to DMARD SCA